Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Age Of Colon Cancer Patients Affects Chemotherapy Combination Outcomes
The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists who presented their findings at the American Society of Clinical Oncology"s (ASCO) annual meeting in Orlando, Fla.
generic viagra online
Health Care 101: Key Challenges In The Debate
Several news organizations had explainers detailing the ongoing the health reform debate.
News of the day
Breast Cancer Drug Shows Promise Against Serious Infections
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. Some scientists suspected that tamoxifen has antifungal properties; now new research from the University of Rochester Medical Center shows that it actually kills fungus cells and stops them from causing disease.
Oncology

At American Diabetes Association Meeting, 2 Preclinical Abstracts Published By Versartis

Versartis, Inc., a new company developing novel biologics with enhanced properties for patients with metabolic diseases, published abstracts for preclinical data on its two product candidates, VRS-859 (exenatide-rPEG) and VRS-808 (glucagon-rPEG), at the American Diabetes Association Scientific Sessions annual meeting in New Orleans. Versartis, through a unique licensing agreement with Amunix, Inc., uses the proprietary Amunix recombinant PEGylation (rPEG) technology to extend the half life of established biologics. The Versartis compounds in development have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development. "With VRS-859, we have a product candidate that may become a "best in class" GLP-1 analog for the treatment of type 2 diabetes. This compound has similar preclinical efficacy to exenatide in animal models; and the pharmacokinetics in four species support monthly dosing in humans. VRS-859 can also be administered in a small volume with a small gauge needle," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "VRS-808 has the potential to prevent nocturnal hypoglycemia in type 1 diabetes, an unmet medical need," Dr. Cleland continued. "VRS-859 and VRS-808 did not have significant toxicology at very high doses in preclinical studies, including a lack of immunogenicity in all studies. We look forward to moving these products rapidly into human clinical trials to benefit diabetes patients." Abstracts: Exenatide: 1994-PO - "An Extended Half-life Exenatide Construct for Weekly Administration in the Treatment of Diabetes Mellitus" Glucagon: 2001-PO - "An Extended Half-life Glucagon Construct for the Prevention of Nocturnal Hypoglycemia" Debra Bannister Versartis, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009